News
-
-
-
-
-
PRESS RELEASE
2025-2026 half-year results : EBITDA margin at 6.5% of revenue - Positive free cash flow and continued reduction in net debt
Prismaflex International reports resilient financial results for the 2025-2026 six-month period, with total sales slightly down but solid EBITDA and positive net result, focusing on debt reduction and commercial initiatives -
-
-
-
PRESS RELEASE
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
Valneva reports positive final phase 2 antibody persistence and safety results for children with its Chikungunya vaccine IXCHIQ®. Twelve-month data supports full dose selection for Phase 3 trial -